Core Viewpoint - BioAtla, Inc. has secured a total of $7.5 million in advance funding through agreements with Yorkville Advisors and Anson Advisors, aimed at maintaining operational momentum while finalizing a strategic partnership that is expected to enhance shareholder value [1][2][7] Financial Agreements - The pre-paid advance agreement involves $7.5 million purchased at 95% of face value, resulting in gross proceeds of $7.125 million at closing, with an interest rate of 4% [2] - The Standby Equity Purchase Agreement allows Yorkville to purchase up to $15 million of common stock at a 3% discount to market prices over three years, contingent on certain conditions [1][2] Strategic Partnership - The company is in advanced stages of finalizing a strategic transaction with a potential partner, with expectations to complete this by year-end [2][7] - These financial agreements are designed to provide flexibility and support operations during the partnership finalization process [7] Company Overview - BioAtla is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, with operations in San Diego and Beijing [6] - The company utilizes its proprietary CAB platform technology to create novel monoclonal and bispecific antibodies, aiming for selective targeting and reduced toxicity compared to traditional antibodies [6] Product Pipeline - Ozuriftamab vedotin (Oz-V) is a key clinical asset targeting ROR2 in various solid tumors, with FDA Fast Track Designation for recurrent or metastatic SCCHN [8] - BA3182, a bispecific T-cell engager antibody, is under Phase 1 study for advanced adenocarcinoma, designed for selective binding in the tumor microenvironment [9]